Have a Question? Use Our New Chat Feature! Chat with our Medical Information Specialists by clicking on the Chat with us now available in the lower right corner of this screen.
Krupa Sivamurthy
Executive Medical Director (Immunology), US Medical Affairs
Krupa Sivamurthy has over 12 years of experience in medical affairs. She joined CSL Behring in 2020 as the Hematology Therapeutic Area Lead where she was responsible for products such as Idelvion, Afstyla, Kcentra, Fibrinogen and Albumin. She led the global medical launch of Hemgenix, the first gene therapy for Hemophilia B. She joined the US Medical Affairs team in 2023 as Executive Medical Director of Immunology.
Prior to joining CSL Behring, Krupa held a variety of Medical Leadership roles with expertise in Rare Disease and Global Medical Affairs at Pfizer. She had led the establishment of Medical Affairs team for Sickle Cell Disease.
Krupa earned her Doctor of Medicine degree with a specialization in Pediatrics from MS Ramaiah Medical College, Bangalore, and completed a registrar-ship in Hematology from Christian Medical College, Vellore. After re-locating to Philadelphia, she completed a residency in Pediatrics from Albert Einstein Medical Center and a Fellowship in Pediatric Hematology-Oncology from St Christopher’s Hospital for Children, Philadelphia.
